Community-based Brain Health Program to Address Dementia Risk (C-BBHP)

This is an interventional treatment trial for Dementia Read More

Inclusion Criteria:

1. Participants who are 65 years of age or older.

2. Participants who meet criteria for two or more Alzheimer's Disease and related dementia risk factors:

   1. Family history of Alzheimer's dementia (1st degree relative)
   2. Genetic marker (APOE4++)
   3. Subjective or objective cognitive decline (neuropsychological testing; or self- reported "yes" to the following question: "In the past two years, have you experienced a decline in your memory or thinking?"
   4. Poorly controlled hypertension or diabetes
   5. Physical inactivity <150min/week per Surgeon General guidelines
   6. Social isolation, in which participant rarely or never gets social and emotional support when needed
   7. OR, meet criteria for elevated risk factors, as determined via the Australian National University AD Risk Index (ANU-ADRI) assessment instrument, a questionnaire-based measure that assess fixed and modifiable risk factors for dementia. The ANU-ADRI has been used in multi-modal studies of behavioral change interventions to reduce dementia risk, and scores have been shown to predict the transition from healthy aging to mild cognitive impairment (MCI) - a crucial measure of dementia risk.
3. Participants who are fluent English speakers from the age of 12, per self-report, to ensure reasonable neuropsychological results on key assessments.
4. Participant must have adequate sensorimotor capacity to perform the program, including visual capacity adequate to read from a computer screen at a normal viewing distance, auditory capacity adequate to understand normal speech, and motor capacity adequate to control a computer mouse or a tablet.

Exclusion Criteria:

1. Participants who are not able to provide informed consent
2. Participants who ≤ 25 on the Cognitive Abilities Screening Instrument (CASI), suggestive of cognitive impairment, or ≥ 30, low likelihood of experiencing cognitive decline over 2 years
3. Participants with untreated psychiatric conditions, including substance abuse/dependence disorders, recent hospitalization, ongoing chemotherapy or other cancer treatment
4. Participants enrolled in a concurrent clinical trial involving an investigational pharmaceutical, nutraceutical, medical device, or behavioral treatment that could affect the outcome of this study. However, participation in standard treatments (e.g., occupational therapy) or use of prescribed medications (e.g., anti-depressants) is allowable.
5. Participants using computer-based cognitive training programs or has used it within a month of the consent date
6. Potential participants answers 'yes' to: Question 4 (Active Suicidal Ideation with Intent) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the Columbia-Suicide Severity Rating Scale (C-SSRS) or 'yes' to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on the C-SSRS "Suicidal Behavior" if the ideation or behavior occurred within 2 months from Participant's date of consent.